

**FAT10 Antibody (C-term) Blocking peptide**  
**Synthetic peptide**  
**Catalog # BP11316b****Specification**

---

**FAT10 Antibody (C-term) Blocking peptide - Product Information**

Primary Accession [O15205](#)  
Other Accession [AAD52982](#), [NP\\_006389.2](#)

**FAT10 Antibody (C-term) Blocking peptide - Additional Information**

**Gene ID** 10537

**Other Names**

Ubiquitin D, Diubiquitin, Ubiquitin-like protein FAT10, UBD, FAT10

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**FAT10 Antibody (C-term) Blocking peptide - Protein Information**

**Name** UBD

**Synonyms** FAT10

**Function**

Ubiquitin-like protein modifier which can be covalently attached to target protein and subsequently leads to their degradation by the 26S proteasome, in a NUB1-dependent manner. Probably functions as a survival factor. Conjugation ability activated by UBA6. Promotes the expression of the proteasome subunit beta type-9 (PSMB9/LMP2). Regulates TNF-alpha-induced and LPS-mediated activation of the central mediator of innate immunity NF-kappa-B by promoting TNF-alpha-mediated proteasomal degradation of ubiquitinated-I-kappa-B-alpha. Required for TNF-alpha-induced p65 nuclear translocation in renal tubular epithelial cells (RTECs). May be involved in dendritic cell (DC) maturation, the process by which immature dendritic cells differentiate into fully competent antigen-presenting cells that initiate T-cell responses. Mediates mitotic non-disjunction and chromosome instability, in long- term in vitro culture and cancers, by abbreviating mitotic phase and impairing the kinetochore localization of MAD2L1 during the prometaphase stage of the cell cycle. May be involved in the formation of aggresomes when proteasome is saturated or impaired. Mediates apoptosis in a caspase-dependent manner, especially in renal epithelium and tubular cells during renal diseases such as polycystic kidney disease and Human immunodeficiency virus (HIV)-associated nephropathy (HIVAN).

**Cellular Location**

Nucleus. Cytoplasm. Note=Accumulates in aggresomes under proteasome inhibition conditions

**Tissue Location**

Constitutively expressed in mature dendritic cells and B-cells. Mostly expressed in the reticuloendothelial system (e.g thymus, spleen), the gastrointestinal system, kidney, lung and prostate gland.

**FAT10 Antibody (C-term) Blocking peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**FAT10 Antibody (C-term) Blocking peptide - Images****FAT10 Antibody (C-term) Blocking peptide - References**

Ucisik-Akkaya, E., et al. Mol. Hum. Reprod. 16(10):770-777(2010)Frank, B., et al. Int. J. Cancer (2010) In press :Gong, P., et al. J. Am. Soc. Nephrol. 21(2):316-326(2010)Castellanos-Rubio, A., et al. Hum. Immunol. 71(1):96-99(2010)Barcellos, L.F., et al. PLoS Genet. 5 (10), E1000696 (2009) :